At Geneva’s Vitafoods 2012, Dr. Cees Vermeer, Principal Investigator at VitaK laboratory at Maastricht University, has presented data showing significant benefits for improved bone strength and prevention of cardiovascular aging with daily supplementation of MenaQ7. In the study, 244 healthy postmenopausal women received for 3 years daily 180 µg K2 from MenaQ7 or a placebo. The clinical measurements included bone mineral density, bone strength, and pulse-wave velocity (PWV), the latter evaluating age-related stiffening of blood vessels.
MenaQ7 supplementation provided a statistically significant protection of the most vulnerable bone structures i.e. vertebrae and the hip. One of the important findings from the study was that clinically relevant improvement at the site of the femoral neck became evident no sooner than after 2 and 3 years of MenaQ7 supplementation. This finding explains for the first time why shorter studies typically failed to show benefits of vitamin K on bone health and cardiovascular health.
“This study is a breakthrough for MenaQ7 and for the Vitamin K2 market”, stated Executive Chairman in NattoPharma Frode Bohan “never in history such effects have been scientifically documented with Vitamin K2 at nutritional dosage”.
The MenaQ7 trial showed substantial benefits in preventing age-related stiffening of arteries resulting in increase of the PWV in the placebo group, but not in the MenaQ7-group. Previously the positive effects on bone and vascular health have been demonstrated with a pharmacological dose of synthetic forms of vitamin K, of up to 45 milligrams per day. The MenaQ7 study shows for the first time in history of vitamin K evaluation the positive health effects with a “nutritional” dose of vitamin K i.e. a dose that can be obtained from a Western-type diet. Remarkably, the low-dose MenaQ7 effects were even more pronounced than those in trials using a high dose of one of the synthetic forms of vitamin K.
MenaQ7 framstilles som et gjæret ekstrakt hvor K2-vitaminet produseres ved hjelp av bacillus subtilis natto. Denne prosessen gjør det mulig å fremstille en ren form for naturlig K2-vitamin menaquinone-7 (MK- 7). MenaQ7® er det av de kommersielle naturlige K2-vitamintilskuddene som er best klinisk dokumentert og har flere internasjonale patenter.
Se vedlagt bilde og info om hvor produktene kan kjøpes, eller www.menaq7.com for mer informasjon.
NattoPharma Norway har eksklusive rettigheter til MenaQ7. Selskapet har startet et flerårig forskningsprogram med VitaK for å dokumentere og videreutvikle bruken av naturlig K2-vitamin i matvarer og kosttilskudd. Se www.nattopharma.com for mer informasjon.